BioNTech SE (BNTX) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
BioNTech’s revenue went from $74M in fiscal 2017 to $3.4B in fiscal 2025, growth of about 61.2% a year.
Net income in fiscal 2025 was -$1.3B, a net margin of -39.6%; the best year in this period was 2021 with $11.7B.
Over the twelve months to September 30, 2026, revenue was $2.7B and net income -$1.6B.
Free cash flow was $330M in fiscal 2025 and positive in 4 of the 9 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B | $3.4B | $2.9B | $4.2B | $18.5B | $21.5B | $592M | $122M | $146M | $74M |
| Gross profit | — | $2.6B | $2.3B | $3.6B | $15.3B | $18.2B | $519M | $102M | $130M | $63M |
| Operating income | — | -$1.7B | -$1.4B | $763M | $13.5B | $17.3B | -$101M | -$204M | -$62M | -$73M |
| Net income | -$1.6B | -$1.3B | -$691M | $1.0B | $10.1B | $11.7B | $19M | -$201M | -$55M | -$103M |
| EPS (diluted) | $-6.49 | $-5.31 | $-2.75 | $4.09 | $40.06 | $46.41 | $0.07 | $-0.80 | $-0.22 | $-0.41 |
| R&D | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +18.0% | −32.3% | −77.1% | −14.1% | +3531.6% | +385.1% | −16.5% | +97.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$254M | $536M | $216M | $5.9B | $14.5B | $1.0B | -$17M | -$223M | -$67M | -$63M |
| Capital spending | -$270M | -$206M | -$298M | -$276M | -$351M | -$144M | -$81M | -$43M | -$34M | -$29M |
| Free cash flow | -$524M | $330M | -$82M | $5.7B | $14.1B | $863M | -$98M | -$266M | -$102M | -$92M |
| Dividends paid | — | — | $0 | $0 | $517M | $0 | $0 | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | $125M | $105M | $57M | $116M | $106M | $39M | $34M | $9M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $9.0B | $10.1B | $12.9B | $14.8B | $1.9B | $1.5B | $583M | $471M | $206M |
| Debt | — | — | — | — | — | $341M | $295M | $83M | — | — |
| Equity | — | $22.6B | $20.2B | $22.4B | $21.4B | $13.5B | $1.7B | $554M | $305M | -$58M |
| Total assets | — | $25.8B | $23.4B | $25.4B | $24.8B | $17.9B | $2.8B | $896M | $748M | — |
| Shares (diluted) | 250M | 251M | 251M | 251M | 251M | 251M | 251M | 251M | 251M | 251M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 77.6% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Operating margin | — | -48.9% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Net margin | -60.9% | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.1% | -164.9% | -37.6% | -139.1% |
| FCF margin | -19.7% | 9.8% | -2.9% | 134.1% | 76.5% | 4.0% | -16.5% | -218.3% | -69.6% | -124.8% |
| ROIC | — | -5.8% | -6.7% | 2.7% | 45.9% | 85.7% | -4.0% | -31.9% | -16.0% | — |
| ROE | — | -5.9% | -3.4% | 4.6% | 47.0% | 86.5% | 1.1% | -36.3% | -18.0% | 177.7% |
Frequently asked questions
What is BioNTech’s annual revenue?
$3.4B in fiscal 2025 and $2.7B over the twelve months to September 30, 2026.
How much profit does BioNTech make?
Net income was -$1.3B in fiscal 2025 (net margin -39.6%).
Is BioNTech’s revenue growing?
Yes: revenue rose 18.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.